SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: ted who wrote (556)2/3/1999 4:57:00 PM
From: Dan Spillane  Respond to of 1298
 
I think the broad CEGE patent covers delivery to ANYWHERE in the nervous system. But its not just that patent, it is the 300 or so others...haha! Moreover, beyond the patent, they are able to prove they can affect actual diseases using the delivery; in this respect it seems they are ahead of others like TGEN.



To: ted who wrote (556)2/4/1999 10:31:00 PM
From: JMarcus  Read Replies (1) | Respond to of 1298
 
Besides CEGE and TGEN, AVGN also has an aav vector. It would be most interesting to hear what each company says about its own patent position vis a vis those of the competing aav vector companies.

Marc


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News